ArticleTranslational cancer research2019
LncRNA SNHG1 upregulates ROCK2 to reduce cisplatin sensitivity of NSCLC cells by targeting miR-101-3p.
Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- High SNHG expression may predict a poor lung cancer prognosis based on a meta-analysis.BMC cancer · 2023Pooled it
- LncRNA SNHG1: role in tumorigenesis of multiple human cancers.Cancer cell international · 2023Review
- Emerging role of non-coding RNAs in resistance to platinum-based anti-cancer agents in lung cancer.Frontiers in pharmacology · 2023Review
- Identification of Hypoxia-Related Prognostic Signature and Competing Endogenous RNA Regulatory Axes in Hepatocellular Carcinoma.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCisplatin is the most commonly used chemotherapy drug in clinical settings, and decreased sensitivity or resistance to cisplatin is the main cause of chemotherapy failure or death among cancer patients. Long non-coding RNA (lncRNA) SNHG1 is highly expressed in non-small cell lung cancer (NSCLC) tissues and promotes the proliferation of NSCLC cells, but the effect of SNHG1 on cisplatin sensitivity of NSCLC cells is unclear.
methodsWe compared the expression of SNHG1 in cisplatin-sensitive and insensitive NSCLC tissues and explored the molecular mechanism of SNHG1 regulation of the sensitivity of NSCLC cells to cisplatin
resultsWe found that SNHG1 is upregulated in cisplatin insensitive NSCLC tissues and cells, and that it can regulate cisplatin sensitivity of NSCLC cells
conclusionsIn summary, our results provide novel mechanistic insights into the role of SNHG1/miR-101-3p/ROCK2 signaling in cisplatin resistance of NSCLC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.